Table 1.
Induction consolidation and maintenance studies in myeloma
| Group | Induction | Transplant type: response | Consolidation | Maintenance | Reference |
|---|---|---|---|---|---|
| Medical Research Council | CTd | Single: CR in 50% | No | Thalidomide vs 0 | 4 |
| Dana-Farber Cancer Institute | VRd | Single in 28: PFS in 92% at 1 y | No | Not in transplanted patients | 5 |
| European Myeloma Network | Carfilzomib, thalidomide, dexamethasone | Single: ≥VGPR in 60% | Carfilzomib, thalidomide, dexamethasone | No | 6 |
| Intergroupe Francophone du Myelome | Vd | Single: ≥VGPR in 54% | Lenalidomide ×2 | Lenalidomide vs 0 | 7 |
| Program a Espanol de Tratamientos en Hematologica | VTd | Single: ≥CR in 46% | No | Interferon vs thalidomide vs bortezomib thalidomide | 8 |
| Italian Group for Adult Hematologic Diseases | VTd | Tandem: ≥VGPR in 89% | VTd ×2 | Dexamethasone | 9 |
| Dutch-Belgian Hemato-Oncology Cooperative Group and the German Multicenter Myeloma Group | PAD | Single (n = 210) and tandem (n = 142): CR or near-CR in 49% | No | PAD ×2 y | 10 |
| European Myeloma Network | VMP ×4 | Single vs tandem* | VRd ×2 vs 0 | Lenalidomide | 11 |
| Dana-Farber Cancer Institute | VRd | Single vs 0* | No | Lenalidomide | 12 |
| International | CRd | Single vs CRd: PFS in 60% vs 38% at 3 y | CRd in nontransplant arm | Lenalidomide vs lenalidomide prednisone | 3 |
CRd, cyclophosphamide, lenalidomide, and dexamethasone; CTd, cyclophosphamide, thalidomide, and dexamethasone; PAD, bortezomib, doxorubicin, and dexamethasone; Vd, bortezomib, dexamethasone.
*
Clinical trial in progress.